Recombinant c-MET anticorps

N° du produit ABIN7127616

Détail du produit anti-c-MET anticorps

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp c-MET est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Réactivité croisée: Humain

Purification: Affinity-chromatography

Immunogène: A synthesized peptide derived from human Met (c-Met)

Clone: 2D12

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200, IF:1:20-1:200, FC:1:20-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur c-MET

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: MET (MET Produits)

Synonymes: anticorps AUTS9, anticorps HGFR, anticorps RCCP2, anticorps c-Met, anticorps AI838057, anticorps HGF, anticorps Par4, anticorps Hgfr, anticorps c-met, anticorps MET, anticorps C-MET, anticorps met, anticorps met-A, anticorps MET proto-oncogene, receptor tyrosine kinase, anticorps met proto-oncogene, anticorps MET proto-oncogene, receptor tyrosine kinase L homeolog, anticorps MET, anticorps Met, anticorps met.L

Sujet:

Background: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).

Aliases: Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met), MET

UniProt: P08581

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor